These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 27639633)

  • 1. Clinical evidence supporting genomic tests in early breast cancer: Do all genomic tests provide the same information?
    Markopoulos C; van de Velde C; Zarca D; Ozmen V; Masetti R
    Eur J Surg Oncol; 2017 May; 43(5):909-920. PubMed ID: 27639633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic and predictive indicators in early-stage breast cancer and the role of genomic profiling: Focus on the Oncotype DX
    Curtit E; Mansi L; Maisonnette-Escot Y; Sautière JL; Pivot X
    Eur J Surg Oncol; 2017 May; 43(5):921-930. PubMed ID: 28087099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK.
    Loncaster J; Armstrong A; Howell S; Wilson G; Welch R; Chittalia A; Valentine WJ; Bundred NJ
    Eur J Surg Oncol; 2017 May; 43(5):931-937. PubMed ID: 28111076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncotype DX
    Rath MG; Uhlmann L; Fiedler M; Heil J; Golatta M; Dinkic C; Hennigs A; Schott S; Ernst V; Koch T; Sohn C; Brucker C; Rom J
    Arch Gynecol Obstet; 2018 Feb; 297(2):443-447. PubMed ID: 29236174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Budget impact analysis of gene expression tests to aid therapy decisions for breast cancer patients in Germany.
    Lux MP; Nabieva N; Hildebrandt T; Rebscher H; Kümmel S; Blohmer JU; Schrauder MG
    Breast; 2018 Feb; 37():89-98. PubMed ID: 29128582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
    Harris LN; Ismaila N; McShane LM; Andre F; Collyar DE; Gonzalez-Angulo AM; Hammond EH; Kuderer NM; Liu MC; Mennel RG; Van Poznak C; Bast RC; Hayes DF;
    J Clin Oncol; 2016 Apr; 34(10):1134-50. PubMed ID: 26858339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of PONDx, a prospective multicenter study of the Oncotype DX
    Curtit E; Vannetzel JM; Darmon JC; Roche S; Bourgeois H; Dewas S; Catala S; Mereb E; Fanget CF; Genet D; Forest AM; Bernier C; Pivot X
    Breast; 2019 Apr; 44():39-45. PubMed ID: 30634106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Utility of Genomic Assay in Node-Positive Early-Stage Breast Cancer.
    Pauls M; Chia S
    Curr Oncol; 2022 Jul; 29(7):5139-5149. PubMed ID: 35877267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer assessment tools and optimizing adjuvant therapy.
    Oakman C; Santarpia L; Di Leo A
    Nat Rev Clin Oncol; 2010 Dec; 7(12):725-32. PubMed ID: 20975745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Economic assessment of the routine use of Oncotype DX® assay for early breast cancer in Franche-Comte region].
    Nerich V; Curtit E; Bazan F; Montcuquet P; Villanueva C; Chaigneau L; Cals L; Méneveau N; Dobi E; Altmotlak H; Algros MP; Choulot MJ; Nallet G; Limat S; Mansion S; Pivot X
    Bull Cancer; 2014; 101(7-8):681-9. PubMed ID: 25091650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast Cancer.
    Ma CX; Bose R; Ellis MJ
    Adv Exp Med Biol; 2016; 882():125-54. PubMed ID: 26987533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors influencing Oncotype DX use in the management of early breast cancer: a single centre experience.
    Zhu X; Dent S; Paquet L; Zhang T; Graham N; Song X
    Eur J Cancer; 2014 Oct; 50(15):2544-9. PubMed ID: 25129366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
    Partin JF; Mamounas EP
    Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2-) breast cancer: When might multigene assays be of value?
    Aapro M; De Laurentiis M; Rea D; Bargallo Rocha JE; Elizalde R; Landherr L; Linderholm B; Mamounas E; Markopoulos C; Neven P; Petrovsky A; Rouzier R; Smit V; Svedman C; Schneider D; Thomssen C; Martin M
    Breast; 2017 Jun; 33():191-199. PubMed ID: 28441617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additional prognostic value of the 70-gene signature (MammaPrint(®)) among breast cancer patients with 4-9 positive lymph nodes.
    Saghatchian M; Mook S; Pruneri G; Viale G; Glas AM; Guerin S; Cardoso F; Piccart M; Tursz T; Delaloge S; van't Veer L
    Breast; 2013 Oct; 22(5):682-90. PubMed ID: 23347730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.
    Albain KS; Paik S; van't Veer L
    Breast; 2009 Oct; 18 Suppl 3():S141-5. PubMed ID: 19914534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical utility of genetic signatures in selecting adjuvant treatment: Risk stratification for early vs. late recurrences.
    Hayes DF
    Breast; 2015 Nov; 24 Suppl 2():S6-S10. PubMed ID: 26238437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial experience with the Oncotype DX assay in decision-making for adjuvant therapy of early oestrogen receptor-positive breast cancer in Hong Kong.
    Cheung PS; Tong AC; Leung RC; Kwan WH; Yau TC
    Hong Kong Med J; 2014 Oct; 20(5):401-6. PubMed ID: 24948666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Prospective Comparison of the 21-Gene Recurrence Score and the PAM50-Based Prosigna in Estrogen Receptor-Positive Early-Stage Breast Cancer.
    Alvarado MD; Prasad C; Rothney M; Cherbavaz DB; Sing AP; Baehner FL; Svedman C; Markopoulos CJ
    Adv Ther; 2015 Dec; 32(12):1237-47. PubMed ID: 26610383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe.
    Blok EJ; Bastiaannet E; van den Hout WB; Liefers GJ; Smit VTHBM; Kroep JR; van de Velde CJH
    Cancer Treat Rev; 2018 Jan; 62():74-90. PubMed ID: 29175678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.